Plexxikon, a member of the Daiichi Sankyo Group, is a leader in the discovery and development of novel, small molecule pharmaceuticals. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical and preclinical stage programs in a number of therapeutic areas and disease indications. Plexxikon’s platform enables the design of highly selective and targeted medicines, supporting the company’s broader strategy to develop personalized medicines.

Biotechnology

Plexxikon

Chao Zhang

Patrick Womack

Michelle Broughton

Plexxikon's CEO and Executive Team includes Jackie Walling and 3 others.

CEO and Executive Team

About

Team members

Other teams at Plexxikon

Leadership Team